FDA budget cuts proposed for fiscal 1998 are "troubling," patient groups tell HHS.
FDA FY 1998 BUDGET PROPOSAL RISKS "WEAKENING" AGENCY, PATIENT GROUPS assert in a Feb. 12 letter to HHS Secretary Shalala. Members of the Patients' Coalition write that "the medical device and import user fees in the FY 1998 budget appear to be a deficit-reduction mechanism with the serious consequence of weakening FDA." The Clinton Administration budget proposal would cut federal appropriations to FDA by 8%, but would use new fees collected across the agency to produce a net 6% increase in funding, to $1.06 bil. ("The Pink Sheet" Feb. 10, p. 9).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth